Rad 9 as a diagnostic,prognostic,and therapeutic tool for prostate cancer
OwnerHoward B. Lieberman, Aiping Zhuinventors
Life of this patent
Estimating the term…
Abstract
This disclosure provides a method of treating a human subject having a cancer which comprises administering to the subject a nucleic acid so as to inhibit expression of human RAD9 protein in a cell of the cancer so as to thereby treat the human subject. This disclosure also provides methods of assessing gains in prostate cancer therapy and detecting prostate cancer.
Claims40
A method of treating a subject having a cancer which comprises administering to the subject a nucleic acid which inhibits expression of a human RAD9 gene so as to thereby treat the human subject.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method of treating a subject having a cancer which comprises administering to the subject an agent which decreases methylation of a human RAD9-encoding nucleic acid in a cell of the cancer so as to thereby treat the subject.
A composition comprising (i) a short interfering nucleic acid directed to a nucleic acid encoding human RAD9 and (ii) a carrier.
(canceled)
(canceled)
40-57. (canceled)
Dependencies are inferred from the claim text.